Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$29.1K Sell
6,319
-885
-12% -$5.89K ﹤0.01% 6695
2026
Q1
$49.7K Sell
7,204
-53,085
-88% -$516K ﹤0.01% 6424
2025
Q4
$609K Buy
60,289
+47,496
+371% +$674K ﹤0.01% 5412
2025
Q3
$164K Buy
+12,793
New +$167K ﹤0.01% 5965
2025
Q1
– Sell
-980
Closed -$17.6K – 8181
2024
Q4
$17.6K Buy
+980
New +$19K ﹤0.01% 6607
2024
Q1
– Sell
-280
Closed -$5.43K – 7924
2023
Q4
$5.43K Buy
280
+275
+5,500% +$5.15K ﹤0.01% 6820
2023
Q3
$107 Sell
5
-94
-95% -$2.35K ﹤0.01% 7440
2023
Q2
$2.63K Buy
99
+84
+560% +$2.34K ﹤0.01% 7135
2023
Q1
$540 Sell
15
-148
-91% -$6.49K ﹤0.01% 7419
2022
Q4
$6.7K Buy
163
+152
+1,382% +$8.75K ﹤0.01% 7073
2022
Q3
$0 Sell
11
-64
-85% -$4.27K ﹤0.01% 7821
2022
Q2
$5K Buy
75
+70
+1,400% +$8.68K ﹤0.01% 7404
2022
Q1
$1K Buy
+5
New +$825 ﹤0.01% 7856

Other funds holding NVX

Morgan Stanley's NVX Position: Q2 2026 in Review

Morgan Stanley reduced its NOVONIX (NVX) stake by 12% in Q2 2026, selling an estimated $5.89K and leaving 6,319 shares worth $29.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6695.

Morgan Stanley first reported a position in NVX in Q1 2022 and has held it in 13 quarters since. The position peaked at $609K in Q4 2025. 25 funds tracked by Wall St. Rank hold NVX as of Q2 2026.

  • Morgan Stanley held 6,319 shares of NOVONIX worth $29.1K as of Q2 2026.
  • Morgan Stanley sold 885 NOVONIX shares in Q2 2026, an estimated $5.89K.
  • NOVONIX made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6695 holding.
  • Morgan Stanley first reported a position in NOVONIX in Q1 2022 and has held it in 13 quarters since.
  • Morgan Stanley's NOVONIX position peaked at $609K in Q4 2025.
  • 25 funds tracked by Wall St. Rank held NOVONIX as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.